Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terpene-enriched CBD oil for children with ADHD
MOH_2024-07-01_013493Phase 2Not yet recruiting
- Sponsor
- Bazelet Nehushtan
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing CBD oil then CBD oil with Placebo then CBD oil (2 arms). Primary endpoints: Change in Conners Parent Questionnaire hyperactivity score and Change in Conners Parent Questionnaire inattention score. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on MOH_2024-07-01_013493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-01_013493.